Noxopharm Ltd. has released a press release.
Novel oligonucleotides data presented at Options Conference
Earlier from Noxopharm
- Appendix 4E - Preliminary Financial Report
- New preclinical data supports immuno-oncology approach
- Quarterly Activities/Appendix 4C Cash Flow Report
- SOF-SKN manufacturing begins to ensure clinical trial readi